PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1798780
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1798780
Global Plantar Fasciitis Treatment Market Growth, Size, Trends Analysis - By Treatment Type, By Indication, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Plantar Fasciitis Treatment Market Introduction and Overview
According to SPER market research, 'Global Plantar Fasciitis Treatment Market Size- By Treatment Type, By Indication, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Plantar Fasciitis Treatment Market is predicted to reach 3.27 billion by 2034 with a CAGR of 9.57%.
Plantar fasciitis treatment encompasses a range of therapeutic approaches aimed at relieving symptoms and addressing the root causes of plantar fasciitis, which is a prevalent foot condition marked by inflammation and irritation of the plantar fascia. This thick band of tissue extends along the foot's base, connecting the heel bone to the toes.
Restraints: Factors impeding the treatment market for plantar fasciitis involve the substantial expense associated with advanced therapies, including shock wave therapy and surgical options, which may be financially daunting for certain patients, particularly in economically disadvantaged areas. Furthermore, the insufficient awareness regarding plantar fasciitis and its corresponding treatments among various individuals is obstructing market expansion.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Treatment Type, By Indication, By End-User
Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered 3M, A. Algeo Ltd, Bauerfeind USA Inc, Hanger, Inc, OrthoBethesda, OrthoMed, Inc, Ottobock, Pfizer, Inc, Revance Therapeutics, Inc, Sanofi.
Global Plantar Fasciitis Treatment Market Segmentation:
By Treatment Type: Based on the Treatment Type, Global Plantar Fasciitis Treatment Market is segmented as; Therapy, Medication Therapy, Surgery.
By Indication: Based on the Indication, Global Plantar Fasciitis Treatment Market is segmented as; Mild, Moderate, Severe.
By End-User: Based on the End-User, Global Plantar Fasciitis Treatment Market is segmented as; Hospitals, Orthopedic Clinics, Physiotherapy Centers, Other End-User.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
Table of Contents
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Plantar Fasciitis Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Plantar Fasciitis Treatment Market
7. Global Plantar Fasciitis Treatment Market, By Treatment Type (USD Million) 2021-2034
- 7.1. Therapy
- 7.1.1. Orthotic devices
- 7.1.2. Shockwave therapy
- 7.1.3. Ultrasound therapy
- 7.1.4. Other therapies
- 7.2. Medication Therapy
- 7.2.1. Nonsteroidal anti-inflammatory drugs (NSAIDs)
- 7.2.2. Corticosteroid injections
- 7.2.3. Topical pain relievers
- 7.3. Surgery
- 7.3.1. Plantar fascia release
- 7.3.2. Gastrocnemius recession
- 7.3.3. Tendon transfer
8. Global Plantar Fasciitis Treatment Market, By Indication (USD Million) 2021-2034
- 8.1. Mild
- 8.2. Moderate
- 8.3. Severe
9. Global Plantar Fasciitis Treatment Market, By End-User (USD Million) 2021-2034
- 9.1. Hospitals
- 9.2. Orthopedic Clinics
- 9.3. Physiotherapy Centers
- 9.4. Other End-User
10. Global Plantar Fasciitis Treatment Market, (USD Million) 2021-2034
- 10.1. Global Plantar Fasciitis Treatment Market Size and Market Share
11. Global Plantar Fasciitis Treatment Market, By Region, (USD Million) 2021-2034
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
12. Company Profile
- 12.1. 3M
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. Algeo Ltd
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. Bauerfeind USA Inc
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. Hanger, Inc
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. OrthoBethesda
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. OrthoMed, Inc
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. Ottobock
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Pfizer, Inc
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
- 12.9. Revance Therapeutics, Inc
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Sanofi
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
- 12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
